ClinicalTrials.gg
CompletedNCT05172206RELOADUpdated Mar 28, 2025

Symptom-based Rehabilitation Compared to Usual Care in Post-COVID - a Randomized Controlled Trial

An interventional study of symptom-focused rehabilitation and usual care in COVID-19 and Long-COVID, sponsored by Schön Klinik Berchtesgadener Land. Completed at 8 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-28.

Primary conditionPost-Acute COVID-19 SyndromeRegistry: COVID-19ReclassifiedWhy we changed it
Registry
COVID-19 — the first condition term the registry derived for this study.
ClinicalTrials.gg
Post-Acute COVID-19 Syndrome
Why
  1. The study's listed conditions name Post-Acute COVID-19 Syndrome, a narrower term within COVID-19.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Schön Klinik Berchtesgadener Land · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany — 14 open to participants now, 17 under way, 2 of them phase 3. Post-Acute COVID-19 Syndrome · Germany.

Enrollment
11th of 28
132 · median 108
Started
2022
with 8 others
No phase
20 of 41
7 open now
Registered
2nd of 41
by date
Lead sponsor
3 of 41
Schön Klinik Berchtesgadener Land

Among the 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany, this one is the 11th largest by enrollment of the 28 interventional ones that give a count, is one of 9 that started in 2022, is one of 20 with no phase, and was the 2nd registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

14 of the 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany, or all of them as a file.
02

Study summary

Inpatient, multimodal rehabilitation represents one of the most important interventions in the disease management of post/long COVID. Different professional societies, including the German Society of Pneumology and the European Respiratory Society, recommend rehabilitation intervention to reduce the sequelae of COVID-19. However, from the perspective of science and practice, there are relevant areas that have been insufficiently investigated and are essential for the treatment success of post/long COVID patients:

  • Differentiation of rehabilitation effects from natural recovery after COVID-19.
  • Lack of personalized and symptom-based treatment approaches that can address the heterogeneity of symptoms in post/long COVID
  • Lack of uniform, high-quality rehabilitation standards in post-/long-COVID.

Therefore, post-COVID patients will be recruited at several post-COVID practices around Germany and randomized to receive (A) a rehabilitation program or (B) usual care. The primary objective of this randomized controlled trial (RCT) is to investigate whether a 3-week symptom-oriented, inpatient, multidisciplinary rehabilitation intervention, whose content focus is standardized according to cluster assignment (fatigue, cognition, soma), has a positive effect on the quality of life (primary outcome) in post-COVID syndrome patients compared to a usual care group (standard outpatient care). All study participants will be provided with a continuous telemonitoring system (SaniQ app) throughout the study period. After the interventional phase, there will be a 3 months follow-up assessment to evaluate the maintenance effects of COVID rehabilitation.

03

Conditions studied

  • COVID-19
  • Long-COVID

Browse trials for

Keywords

  • rehabilitation
  • intervention
  • quality of life
  • long-COVID
  • post-COVID syndrome
  • sequelae
  • recovery
04

In context

Post-Acute COVID-19 Syndrome Reclassified

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

This study's enrollment of 132 is above the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.

Browse Post-Acute COVID-19 Syndrome studies →

Lead sponsor

Schön Klinik Berchtesgadener Land is the lead sponsor of 51 studies on the registry; 2 are open to participants now.

Compared within Post-Acute COVID-19 Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is COVID-19. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Post-COVID Syndrome according to World Health Organisation definition (persistent symptoms for at least 3 months after PCR-test confirmed SARS-CoV 2 infection)

Exclusion criteria

Exclusion Criteria:

  • no walking ability
  • not able to operate smartphone apps
  • rehabilitation program within the previous 6 months
06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
132 participants (actual)

Study arms

  • Active comparator
    Symptom-focused Rehabilitation

    Patients in this arm will be referred to a 3-week inpatient comprehensive rehabilitation program. Initially, patients will be classified into one out of three clusters namely: Cluster A (Fatigue), Cluster B (cognition), or Cluster C (physical). The content of the rehabilitation program will be individually adapted according to the patient's most relevant symptom cluster.

    Other: symptom-focused rehabilitation

  • Other
    Usual Care

    Patients in this arm do not receive any intervention beyond usual care during the study phase. However, all patients in this group will get the opportunity to also receive a rehabilitation program after the study phase.

    Other: usual care

Interventions

  • Othersymptom-focused rehabilitation

    Patients in this arm will be referred to a 3-week inpatient comprehensive rehabilitation program. Initially, patients will be classified into one out of three clusters namely: Cluster A (Fatigue), Cluster B (cognition), or Cluster C (physical). The content of the rehabilitation program will be individually adapted according to the patient's most relevant symptom cluster.

  • Otherusual care

    Patients in this arm do not receive any intervention beyond usual care during the study phase. However, all patients in this group will get the opportunity to also receive a rehabilitation program after the study phase.

07

What researchers measure

Primary outcomes

  1. Change from baseline Quality of life assessed by Short Form - 12 Questionnaire at week 4 and week 12

    the scale of the physical and mental Health component summary score ranges from minimum 0 to maximum 100 points with higher scores indicating better quality of life

    Time frame: baseline, week 4, week 12

Secondary outcomes

  1. Change from baseline COVID-related symptoms at week 4 and week 12

    the number of COVID-symptoms will recorded as well as their intensity will be rated on a scale from 0 \[not relevant\] until 10 \[very severe symptom\].

    Time frame: baseline, week 4, week 12

  2. Change from baseline lung function at week 4 and week 12

    following Parameters will be collected: forced expiratory volume in 1 sec, peak flow, forced vital capacity, total lung capacity, diffusion lung capacity for carbonmonoxide

    Time frame: baseline, week 4, week 12

  3. Change from baseline blood gas analysis at week 4 and week 12

    following parameters will be collected at rest and at the end of an incremental cycle test: partial pressure for oxygen and carbon dioxide

    Time frame: baseline, week 4, week 12

  4. Change from baseline Cardiac Doppler echocardiography at week 4 and week 12

    Left and right heart echocardiography will be performed

    Time frame: baseline, week 4, week 12

  5. Change from baseline laboratory parameters at week 4 and week 12

    blood samples will be taken from venous blood

    Time frame: baseline, week 4, week 12

  6. Change from baseline exercise performance at week 4 and week 12

    incremental cardiopulmonary exercise testing will be performed with spirometry

    Time frame: baseline, week 4, week 12

  7. Change from baseline health care service needs at week 4 and week 12

    Number of visits at the general practitioner, pulmonologist, psychologist, physiotherapist, COVID-ambulance, hospital admission until the last visit will be recorded

    Time frame: baseline, week 4, week 12

  8. Change from baseline working capability at week 4 and week 12

    number of days of incapacity to work until the last visit will be recorded

    Time frame: baseline, week 4, week 12

  9. Change from baseline sleep quality at week 4 and week 12

    Sleep quality will be assessed by using the Pittsburgh Sleep Quality Index (total score ranges from 0 to 21 with higher scores indicating higher impairment)

    Time frame: baseline, week 4, week 12

  10. Change from baseline sleep quality at week 4 and week 12

    daytime sleepiness will be assessed by using the Epworth Sleepiness Scale (total score ranges from 0 to 24 with higher scores indicating higher impairment)

    Time frame: baseline, week 4, week 12

  11. Change from baseline Depression status assessed by Patient Health Questionnaire 9

    the total score ranges from 0 to 27 points with higher scores indicating worse Depression symptoms

    Time frame: baseline, week 4, week 12

  12. Change from baseline Anxiety status assessed by Generalized Anxiety Disorder Scale 7

    the total score ranges from 0 to 21 points with higher scores indicating more anxiety symptoms

    Time frame: baseline, week 4, week 12

  13. Change from baseline resilience assessed by resilience scale 13

    the total score ranges from 13 to 91 points with higher scores indicating higher resilience

    Time frame: baseline, week 4, week 12

  14. Change from baseline cognitive status assessed by Montreal Cognitive Assessment Test

    the total score ranges from 0 to 30 points with higher scores indicating a better cognitive status

    Time frame: baseline, week 4, week 12

  15. Change from baseline dyspnea assessed by Modified Medical Research Counsil score at week 4 and week 12

    the total score ranges from 0 to 4 points with higher scores indicating more dyspnea

    Time frame: baseline, week 4, week 12

  16. Change from baseline dysfunctional breathing assessed by Nijmegen breathing questionnaire at week 4 and week 12

    the total score ranges from 0 to 64 points with higher scores indicating hyperventilation

    Time frame: baseline, week 4, week 12

  17. Change from baseline chronic fatigue syndrome assessed by fatigue assessment scale at week 4 and week 12

    the total score ranges from 10 to 50 points with higher scores indicating more fatigue

    Time frame: baseline, week 4, week 12

  18. Change from baseline chronic fatigue syndrome assessed by canadian consensus criteria at week 12

    the canadian consensus criteria indicate if patients developed a chronic fatigue syndrome/myalgic encephalomyelitis

    Time frame: baseline, week 12

  19. Change from baseline functional status assessed by post-COVID functional status scale at week 4 and week 12

    the total score ranges from 0 to 4 points with higher scores indicating more impairment

    Time frame: baseline, week 4, week 12

  20. Change from baseline physical activity assessed by Garmin watch at week 4 and week 12

    daily total steps per day will be recorded by a Garmin watch linked to the SaniQ App

    Time frame: baseline, week 4, week 12

  21. Change from baseline blood pressure assessed at week 4 and week 12

    blood pressure will be measured at the upper arm using the Aponorm device

    Time frame: baseline, week 4, week 12

  22. Change from baseline oxygen saturation assessed by pulse oximeter at week 4 and week 12

    Beurer pulse oximeter

    Time frame: baseline, week 4, week 12

  23. Change from baseline peak flow assessed by peak flow meter at week 4 and week 12

    peak flow will be assessed by smart one spirometer

    Time frame: baseline, week 4, week 12

08

Study locations

8 sites
  • University Hospital Augsburg
    Augsburg, Germany
  • Praxis Dr. Schrag
    Bad Reichenhall, Germany
  • Pneumologen Lichterfelde Berlin
    Berlin, Germany
  • Praxis im Zentrum Erlangen
    Erlangen, Germany
  • Pneumopraxis Marburg
    Marburg, Germany
  • Lungenärzte am Rundfunkplatz, München
    Munich, Germany
  • Praxis Dr. Roch
    Schwabach, Germany
  • COVID ambulance Prof. Koczulla
    Schönau am Königssee, Germany
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Jan 2024, 20 months.

Of 232 non-industry interventional studies with no phase under Post-Acute COVID-19 Syndrome, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's 20 months is above that.

Counting every sponsor, half of 243 studies reached it within 16 months; a quarter within 7 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2021
First posted
Dec 29, 2021
StartActual
May 20, 2022
Primary completionActual
Jan 25, 2024
CompletionActual
Jan 25, 2024
Last update
Mar 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05172206
Lead sponsor
Schön Klinik Berchtesgadener Land
Collaborators
Bavarian State Office for Health and Food Safety, Praxis im Zentrum Erlangen, Pneumologen Lichterfelde Berlin, Pneumopraxis Marburg, COVID ambulance Philipps-University Marburg, Pneumologie Elisenhof Munich, COVID ambulance Pneumology LMU Munich, COVID ambulance psychology LMU Munich, University Clinic Augsburg, COVID ambulance Schön Klinik Schönau
Responsible party
Prof. Dr. Andreas Rembert Koczulla (Professor, Schön Klinik Berchtesgadener Land) — Principal investigator
First posted
Dec 29, 2021
Start date
May 20, 2022
Primary completion
Jan 25, 2024
Completion
Jan 25, 2024
Last update
Mar 28, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion